Participate in a research study on a muscle regenerating treatment for FSHD
Vita Therapeutics is a cell engineering company harnessing the power of genetics to develop cellular medicines in the areas of neuromuscular diseases. The company utilizes induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.
Vita Therapeutics is currently targeting Facioscapulohumeral Muscular Dystrophy (FSHD) with its product VTA-120, an autologous cell therapy designed to repair and regenerate healthy muscle in patients with FSHD. VTA-120 is currently in the pre-clinical stages and working towards initiating IND-enabling studies with the goal to file an IND (Investigational New Drug) application with the FDA for the first-in-human (FIH) study in the second half of 2025.
Vita Therapeutics will undertake a Phase I/II trial of FSHD patients with the goal of determining the safety and tolerability of IM injection of Vita Therapeutics’ iPSC-derived satellite cells. They are currently recruiting five (5) initial patients to test their ability to manufacture VTA-120 and to ultimately, to evaluate these patients’ potential to participate in Vita’s FIH Clinical Trial.
They are seeking individuals that meet the following criteria:
- Confirmed genetic diagnosis of FSHD1 or FSHD2
- Age 18-65
- Able to walk on flat ground without braces
- No serious other co-morbid health conditions
- Not taking systemic corticosteroid medication.
If you think you meet these requirements, please email Vita Therapeutics.